Dr. Muster is a virologist with particular expertise in influenza viruses and the interferon antagonist nonstructural protein 1 (NS1). As Chief Scientific Officer of Vivaldi, he leads the company’s development of its deltaFLU live attenuated influenza vaccine, which Dr. Muster has advanced into Phase 2 clinical trials. Dr. Muster has contributed to several key inventions in the development of prophylactic and therapeutic vaccines, including discovery of a conserved antigen on HIV, a melanoma-associated retrovirus, and the structure and function of NS1. He has co-authored more than 50 publications in the fields of virology and cancer. He also has founded or co-founded several biotechnology companies including Nuvonis Technologies, Blue Sky Vaccines, and AVIR Green Hills Biotechnology. Previously Dr. Muster was the founder and staff investigator of the Virology group at the Institute of Applied Microbiology, University of Applied Life Sciences, Vienna, and was Head of the Virology Oncology group at the Medical University of Vienna. Dr. Muster earned an Engineering degree in Biotechnology and a PhD in Biotechnology from the University of Applied Life Sciences, Vienna, and was a Research Fellow at Mount Sinai School of Medicine (now the Icahn School of Medicine at Mount Sinai).